Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.

Inclusion Criteria:

Phase I

• Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
• Patients aged ≥ 18 years
• Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data

Phase II

• Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
• Patients aged ≥ 18 years
• Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data

Exclusion Criteria:

• Patients not willing to consent to review of clinical data

Patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.